NCT06067503 2026-04-13
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
Phase 2 Recruiting
Clinical Trials
8 trialsNCT00616967 2026-03-05
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06408168 2026-01-05
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03620643 2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05919108 2025-09-09
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT04252859 2025-05-18
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
University of Utah
Phase 2 Terminated
NCT02764541 2025-05-07
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting